Faricimab (visual impairment due to macular oedema secondary to retinal vein occlusion) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Faricimab (Visusbeeinträchtigung infolge eines Makulaödems bei retinalem Venenverschlusses) – Nutzenbewertung gemäß § 35a SGB V. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Faricimab (visual impairment due to macular oedema secondary to retinal vein occlusion) Benefit assessment according to §35a SGB V1 EXTRACT Project: A24-85 Version: 1.0 Status: 20 Nov 2024 DOI: 10.60584/A24-85_en Extract of dossier assessment A24-85 Version 1.0 Faricimab
Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT Text onlyJournals LibraryNHS NIHR - National Institute for Health and Care ResearchSelectEMEGHRHSDRHTAPGfARPHR AdvancedJournalsEfficacy and Mechanism EvaluationGlobal Health ResearchHealth and Social Care Delivery ResearchHealth Technology AssessmentProgramme with diabetic macular oedema: the DIAMONDS non-inferiority RCTSubthreshold micropulse laser for diabetic macular oedema with central retinal thickness less than 400µ was equivalent to standard threshold laser but required a slightly higher number of laser treatments.Noemi Lois, Christina Campbell, Norman Waugh, Augusto Azuara-Blanco, Mandy Maredza, Hema Mistry, Danny McAuley, Nachiketa Acharya, Tariq M Aslam
Assessment of peripheral oedema Assessment of peripheral oedema - Differential diagnosis of symptoms | BMJ Best PracticeSkip to main contentSkip to search * English (US)EnglishPortuguês中文 * Log in * Personal account * Access through your institution(Open Athens) * Subscribe * Access through your institution * Log in * English (US)EnglishPortuguês中文 HomeSearchSearchHome * About usOverviewWhat of peripheral oedema Menu Close * Overview * Theory * Emergencies * Diagnosis * Resources * Overview * Summary * Theory * Aetiology * Emergencies * Urgent considerations * Diagnosis * Approach * Differentials * Resources * Images and videos * References * Patient information * Calculators Log in or subscribe to access all of BMJ Best PracticeLast reviewed: 9 Dec 2024Last updated: 31
Faricimab (Vabysmo) in age-related macular degeneration or diabetic macular oedema Prescrire IN ENGLISH - Spotlight ''Faricimab (Vabysmo°) in age-related macular degeneration or diabetic macular oedema'', 1 June 2024 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My Prescrire Issue contents * Current issue * Last 12 issues * All issues Topics subscription * Solidarity Subscription Rate * Subscribers: register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Faricimab (Vabysmo°) in age-related macular degeneration or diabetic macular oedema SpotlightEvery month, the subjects in Prescrire’s Spotlight. 100 most recent: 1|10|20|30|40|50|60|70|80|90
Urticaria and angio-oedema Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languageUrticaria and angio-oedema MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:23 Jul 2023Last updated:22 Aug 2023SummaryUrticaria is a skin condition characterised by erythematous, blanching, oedematous, non episodes of hives occurring for 6 weeks or more and has a complex aetiology.Angio-oedema is swelling involving the deeper layers of the subdermis and occurs in association with urticaria in about 40% of cases. It can also occur in the absence of urticaria.Angio-oedema involving the face or neck can potentially compromise the airway and requires prompt airway management.Diagnosis of urticaria and angio
Faricimab (visual impairment due to diabetic macular oedema) ' Benefit assessment acc. to ' 35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Faricimab (Visusbeeinträchtigung infolge eines diabetischen Makulaödems) – Nutzenbewertung gemäß § 35a SGB V. Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Faricimab (visual impairment due to diabetic macular oedema) – Benefit assessment according to §35a SGB V1 EXTRACT Project: A22-109 Version: 1.0 Status: 12 January 2023 Extract of dossier assessment A22-109 Version 1.0 Faricimab ( visual impairment due to diabetic macular oedema 12
Nitrates for Acute Pulmonary Edema, Diuretic Prescriptions for CHF Prevention, POCUS for CHF Diagnosis Emergency Medicine Journal Club ARCHIVES/ CLINICAL TOOLS/ RESIDENTS/ PROCEDURES/ LLSA/ EPT Nitrates for Acute Pulmonary Edema, Diuretic Prescriptions for CHF Prevention, POCUS for CHF DiagnosisThis month JC will be looking at another “bread and butter” ED complaint namely, ED management of the acute heart failure patient. Kelly GS, et al., Low- versus high-dose nitroglycerin infusion in the management of acute pulmonary edema. Am J Emerg Med. 2023 Mar;65:71-75. AppraisalFaselis C, et al., Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure. J Am Coll Cardiol. 2020 Aug 11;76(6):669-679. AppraisalMcGivery K et al., Emergency department ultrasound
Non-steroidal anti-inflammatory agents for treating cystoid macular edema following cataract surgery. Cataract surgery is the most common ambulatory incisional surgery performed in the USA. Cystoid macular edema (CME), the accumulation of fluid in the central retina due to leakage from dilated capillaries, is the most common cause of vision impairment following cataract surgery. Acute CME
Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration Published: 2 January 2024 Driving Better Decision-Making in Healthcare Page 1 Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration Technology Guidance from the MOH Drug Advisory Committee Guidance Recommendations The Ministry of Health’s Drug Advisory Committee has recommended: ✓ Faricimab 6 mg/0.05 mL vial for treating adults with visual impairment due to: ▪ diabetic macular oedema; and ▪ neovascular (wet) age-related macular degeneration. Funding status Faricimab 6 mg/0.05 mL vial is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indications from
Aflibercept 8 mg/0.07 mL (Eylea HD) - For the treatment of diabetic macular edema View of Aflibercept 8 mg/0.07 mL (Eylea HD) | Canadian Journal of Health TechnologiesReturn to Article DetailsAflibercept 8 mg/0.07 mL (Eylea HD)
Faricimab (Vabysmo) - treatment of adult patients with visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) Published 07 October 2024 Advice document SMC2685 faricimab solution for injection (Vabysmo®) Roche 06 September 2024 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission faricimab (Vabysmo®) is accepted for use within NHSScotland. Indication under review: treatment of adult patients with visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO
Aflibercept (Eylea HD) - Diabetic Macular Edema View of Aflibercept (Eylea HD) | Canadian Journal of Health Technologies Return to Article DetailsAflibercept (Eylea HD)